Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:NVO) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $187,270 and 4, calls, for a total amount of $298,402.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $145.0 for Novo Nordisk over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $110.0 to $145.0 in the last 30 days.
Novo Nordisk Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | TRADE | BEARISH | 03/21/25 | $28.0 | $27.2 | $27.2 | $110.00 | $190.4K | 159 | 70 |
| NVO | CALL | SWEEP | BEARISH | 06/20/25 | $10.9 | $10.85 | $10.9 | $145.00 | $52.3K | 4 | 68 |
| NVO | PUT | SWEEP | BULLISH | 09/06/24 | $4.85 | $4.5 | $4.5 | $136.00 | $48.1K | 540 | 219 |
| NVO | PUT | SWEEP | BEARISH | 09/13/24 | $3.1 | $3.05 | $3.1 | $132.00 | $42.4K | 137 | 153 |
| NVO | PUT | SWEEP | BULLISH | 09/06/24 | $4.85 | $4.5 | $4.5 | $136.00 | $35.5K | 540 | 338 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Novo Nordisk
- Currently trading with a volume of 1,270,535, the NVO's price is down by -2.78%, now at $130.79.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 56 days.
What The Experts Say On Novo Nordisk
In the last month, 2 experts released ratings on this stock with an average target price of $160.0.
- An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $160.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
有很多钱可以花的大户对Novo Nordisk采取了明显的看淡态度。
查看诺和诺德（NYSE：NVO）期权历史数据，我们发现了9笔交易。
如果我们考虑每一次交易的具体情况，可以准确地说，33%的投资者持有看好预期，66%持有看淡预期。
从所有的交易中，有5笔是看跌期权，总金额为187,270美元，4笔是看涨期权，总金额为298,402美元。
预计价格目标
考虑到这些合约的成交量和持仓量，看来鲸鱼们在过去的3个月里将诺和诺德的价格区间定在了110.0美元至145.0美元之间。
成交量和未平仓量趋势
在交易期权时，观察成交量和持仓量是一个强大的举措。这些数据可以帮助您追踪给定行权价的诺和诺德期权的流动性和兴趣。下面，我们可以观察在过去30天内，110.0美元至145.0美元的价格区间内，所有诺和诺德鲸鱼交易的看涨和看跌期权的成交量和持仓量的变化情况。
诺和诺德期权活动分析:最近30天
检测到重大期权交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | TRADE | BEARISH | 03/21/25 | $28.0 | $27.2 | $27.2 | $110.00 | $190.4K | 159 | 70 |
NVO | CALL | SWEEP | BEARISH | 06/20/25 | $10.9 | $10.85 | $10.9 | $145.00 | $52.3K | 4 | 68 |
NVO | PUT | SWEEP | BULLISH | 09/06/24 | $4.85 | $4.5 | $4.5 | $136.00 | $48.1K | 540 | 219 |
NVO | PUT | SWEEP | BEARISH | 09/13/24 | $3.1 | $3.05 | $3.1 | $132.00 | $42.4K | 137 | 153 |
NVO | PUT | SWEEP | BULLISH | 09/06/24 | $4.85 | $4.5 | $4.5 | $136.00 | $35.5K | 540 | 338 |
诺和诺德是一家领先的全球医疗保健公司，致力于研发创新药品，帮助患糖尿病的患者过上更长寿、更健康的生活，这一传统已有100多年。这种传统为我们提供了经验和能力，使我们能够推动变革，帮助人们战胜其他严重的慢性疾病，如肥胖症、罕见的血液和内分泌紊乱。我们始终坚信，持久的成功公式是保持专注，长远思考，并以财务、社会和环境负责任的方式做生意。诺和诺德在新泽西州设有美国总部，在7个州加上华盛顿特区拥有商业、生产和研究设施，在全国约有8000名员工。有关更多信息，访问novonordisk-us.com，Facebook、Instagram和X。
作为全球治疗糖尿病品牌市场三分之一的领先者，丹麦的Novo Nordisk公司是世界上提供糖尿病护理产品的主要制造商和市场推广者。该公司制造和销售各种人体和现代胰岛素、GLP-1疗法等可注射糖尿病治疗药物、口服降糖药以及肥胖症治疗药物。Novo Nordisk还有一个生物制药部门（约占营收的10%），专门从事血友病和其他疾病的蛋白质疗法。
经过对诺和诺德期权交易的全面审查，我们将进一步对该公司进行详细审查。 这包括对其当前市场地位和业绩的评估。
Novo Nordisk的现有市场地位
目前成交量为1,270,535，NVO的价格下跌-2.78%，目前为$130.79。
RSI读数表明该股票目前处于中立状态，处于超买和超卖之间。
预计的盈利发布还有56天。
专家对诺和诺德的评价
在过去一个月中，有2位专家发布了这支股票的评级，平均目标价为160.0美元。
期权交易具有更高的风险和潜在回报。精明的交易者通过不断教育自己、调整策略、监控多种因子和密切关注市场动态来管理这些风险。通过Benzinga Pro实时警报了解最新的Novo Nordisk期权交易情况。
